News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 644 results
August 2014
-
Media ReleaseNovartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial- Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen(1)- On all-cause mortality, LCZ696 doubled the effect…
-
Media ReleaseNovartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
-
Media ReleaseNovartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696-- LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF-- PARADIGM-HF is the largest heart…
-
Media ReleaseNovartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696
July 2014
-
Media ReleaseNovartis announces NEJM publication of two pivotal Phase III secukinumab studies demonstrating statistically significant skin clearance in psoriasis patients- Results of two Phase III psoriasis studies show secukinumab, the first psoriasis IL-17A inhibitor filed with regulatory bodies, met all co-primary and key secondary endpoints[1]- A statistically…
-
Media ReleaseNovartis announces NEJM publication of two pivotal Phase III secukinumab studies demonstrating statistically significant skin clearance in psoriasis patients
-
Media ReleaseNovartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation- Designation supports the advancement of CTL019 to help address the unmet need of patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL)- The filing was submitted by the University…
-
Media ReleaseNovartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation
June 2014
-
Media ReleasePivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinomaThe study met the primary endpoint with objective response rates of 41.8% and 32.5% respectively in the 200 mg and 800 mg treatment arms(1,2)Basal cell carcinoma is the most common form of skin…
-
Media ReleasePivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma
Pagination
- ‹ Previous page
- 1
- …
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- …
- 54
- › Next page